CRP and coronary artery disorder: With regard to more-novel biomarkers, the task force categorized measurement of C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (LpPLA2), coronary calcium, carotid intima-media thickness, and ankle/brachial index to be reasonable for refining risk estimation and making clinical decisions in individuals initially classified as at intermediate CHD risk, using classical risk factors.